Paradigm Biocapital Advisors LP Kura Oncology, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.47 Billion
- Q2 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 4,539,381 shares of KURA stock, worth $94.8 Million. This represents 3.78% of its overall portfolio holdings.
Number of Shares
4,539,381
Previous 3,135,387
44.78%
Holding current value
$94.8 Million
Previous $66.9 Million
39.76%
% of portfolio
3.78%
Previous 2.51%
Shares
5 transactions
Others Institutions Holding KURA
# of Institutions
181Shares Held
80.2MCall Options Held
148KPut Options Held
63K-
Suvretta Capital Management, LLC New York, NY7.07MShares$148 Million6.08% of portfolio
-
Black Rock Inc. New York, NY6.97MShares$145 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.81MShares$121 Million4.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY5.41MShares$113 Million2.34% of portfolio
-
Bvf Inc San Francisco, CA4.08MShares$85.2 Million2.57% of portfolio
About Kura Oncology, Inc.
- Ticker KURA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,893,000
- Market Cap $1.4B
- Description
- Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...